BioInvent Reports Positive Phase 1 Data for Cancer Drug BI-1808
BioInvent International AB (OMXSTO:BINV) reported Phase 1 monotherapy trial results for its cancer drug candidate BI-1808. The study showed evidence of single-agent anti-tumor activity with CD8+ T cell infiltration, alongside an excellent safety profile.
The clinical data provides early validation for targeting TNFR2 in patients, helping de-risk dosing and development strategies. Demonstrating efficacy as a standalone treatment expands potential use cases for the asset and strengthens platform credibility.
Development moves forward in an ongoing Phase 1/2a trial. Investors and researchers will monitor confirmation of response rates and treatment durability, as well as results from cohorts evaluating BI-1808 in combination with pembrolizumab.
Key points
- BioInvent reported Phase 1 monotherapy results showing anti-tumor activity for BI-1808.
- The treatment demonstrated an excellent safety profile and CD8+ T cell infiltration in patients.
- Clinical findings validate TNFR2 targeting and help de-risk the candidate's development.
- BI-1808 is currently in a Phase 1/2a trial, including combination testing with pembrolizumab.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did BioInvent report regarding BI-1808?
BioInvent reported Phase 1 monotherapy data demonstrating single-agent anti-tumor activity, CD8+ T cell infiltration, and an excellent safety profile for BI-1808.
What is the current status of BI-1808 development?
BI-1808 is undergoing further evaluation in an active Phase 1/2a clinical trial, which includes testing in combination with pembrolizumab.